Advanced Hybrid Closed Loop system for people living with type 1 diabetes.
MiniMedTM 780G system
Our most advanced insulin pump system with SmartGuardTM automatically*** adjusts insulin delivery and corrects glucose levels every 5 minutes, 24/7 with one infusion set change per week*,1 and no fingerpricks**. The system is compatible with three sensors: Instinct sensor (made by Abbott and designed exclusively for the MiniMedTM 780G system), Simplera SyncTM sensor and GuardianTM 4 sensor.
Things you should know about the MiniMed 780GTM
Anticipates. Adjusts. Corrects.
Anticipates insulin needs. Adjusts insulin delivery. Corrects highs automatically† while helping to protect you from lows1,***.
Improved Outcomes. Improved Satisfaction3,††
Helps increase Time in Range with less effort2. Helps to reach 80% Time in Range3-6,†††.
Meal DetectionTM feature
Automatically**** provides missed bolus forgiveness and helps cover underestimated carb counts.
Now with Instinct sensor. Made by Abbott.
The world's smallest7,8 15-day sensor.
SmartGuardTM technology helps prevent highs and lows4
More about our three sensors
Simplera SyncTM*****
- Automated to help more patients reach glycaemic targets with less effort
- Self-adjusts insulin delivery up to 288 times per day9
- Helps increase Time in Range with less effort2. Helps to reach 80% Time in Range10
- Automatic data transfer to facilitate remote follow-up
- Designed for real life, where carb counting is not always exact9
Instinct Sensor
Our most advanced insulin pump system with SmartGuardTM automatically*** adjusts insulin delivery and corrects glucose levels every 5 minutes, 24/7 with one infusion set change per week*,1 and no fingerpricks**.
- Proven to be accurate, stable, and consistent for 15 full days8,11
- Small, discreet8 and comfortable12 to wear
- One-piece application
Guardian™ 4 sensor
- Integrated CGM with Guardian 4 Sensor & transmitter
- No fingerpricks for calibration required**
MiniMed™ 780G system - SmartGuardTM algorithm
Lou Lintereur, the Chief Engineer of Automated Insulin Delivery Systems at MiniMed, discusses the SmartGuardTM algorithm, a key feature of the MiniMedTM 780G system.
I’ve been a MiniMed girl since I was 12. My insulin pump has given me more freedom and, above all, less mental burden.
Maria
MiniMedTM 780G user
Footnotes
* When used with Medtronic Extended infusion set. Refer to User Guide.
**A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions.
***Refer to User Guide. Some user interaction required.
****Please refer to the MiniMed™ 780G system IFU. These features do not replace the need to bolus before meals.
***** Simplera Sync™ Sensor is currently only available in the UK. We are working with the relevant regulatory bodies in the the Republic of Ireland to make this CGM innovation available to customers in this region as soon as possible.
†Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
††Compared with MDI
†††TIR was reached using the optimal settings that are the combination of glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours for at least 95% of the time. SmartGuard™ feature settings for each single patient must be defined by HCPs based on individual targets and specific needs
References
1.Ilany J, et al. Abstract 416 at the 13th ATTD International Conference. February 2020
2.Collyns OJ, et al. Diabetes Care. 2021;44(4):969-975.
3. Choudhary P, et al. Lancet Diabetes Endocrinol. 2022;10(10):720-731.
4. Choudhary P, et al. Diabetes Technol Ther 2024; 26 (Suppl. 3): S32-S37.
5. Carlson AL, et al. Diabetes Technol Ther. 2022;24(3):178-189.
6. Matejko B, et al. Diabetes Care. 2022;45:2628–2635
7. Among patient-applied sensors.
8. Data on file, Abbott Diabetes Care, Inc.
9. Carlson AL, et al. Poster #97 at the 80th International Conference of the American Diabetes Association, June 202, Chicago/Virtual
10. Medtronic data on file: MiniMed™ 780G data uploaded voluntarily by 12.870 users in EMEA to CareLink™ Personal, from 27 August 2020 to 22 July 2021. Mean 80% TIR reached by 1.784 users using MiniMed ™ 780G with recommended settings of 2 hours active insulin time and 100 mg/dL (5.5 mmol/L) as glucose target for at least 90% of the time.
11. Finger pricks are required if glucose readings and alarms do not match symptoms or expectations.
12. Alva et al. 'Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring System.' Diabetes Therapy 14, no. 4 (2023): 767-776. https://doi.org/10.1007/s13300-023-01385-6.
13. Di Molfetta S, Di Gioia L, Caruso I, et al. Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Metab Res Rev. 2024;40(6):e3842. doi:10.1002/dmrr.3842
14. Data on file, Abbott Diabetes Care, Inc.
15. Fusselman H, et al. FUSS2015D-P - The Extended Wear Infusion Set - A Design for Plastic Waste Reduction. Virtual Diabetes Technology Meeting. 2020
16.Alwan et al. (2023) doi: 10.1177/19322968231185348
Disclaimer
DreaMed Diabetes is a trademark of DreaMed Diabetes. Ltd. The MiniMed™ 780G system algorithm includes technology developed by DreaMed Diabetes.
All products mentioned in the material is CE marked. Please note that the intended use of a product may vary depending on geographical approvals. See the device manual(s) for detailed information regarding the intended use, the procedure, indications, contraindications, warnings, precautions, and potential adverse events. CE-DBA-2600315 ©2026 .Medtronic MiniMed, Inc. MiniMed and MiniMed logo are trademarks of Medtronic MiniMed, Inc. The sensor shape and appearance, Abbott, and “a” logo are marks and/or designs of the Abbott group of companies in various territories and used under license. Sensor image ©2026 Abbott. ™* Third–party brands are trademarks of their respective owners. DreaMed Diabetes is a trademark of DreaMed Diabetes, Ltd. The MiniMed™ 780G system algorithm includes technology developed by DreaMed Diabetes.
Please note that this platform has been developed for UK Healthcare Professionals. Content may not be aligned with local regulations, approvals, or practices in your country. Please contact your MiniMed representative for further information.